Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES AND LONG-TERM LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2021

Other accrued expenses consisted of the following as of June 30, 2021 and December 31, 2020:

SCHEDULE OF OTHER ACCRUED EXPENSES

	June 30, 2021		December 31, 2020
	(unaudited)
Accrued royalties	$	3,320	$	2,710
Upfront Medicare payment		1,174		2,066
Operating lease liability		898		1,027
All others		897		1,182
Accrued professional fees		719		854
Unclaimed property		565		565
Contingent consideration		459		398
Accrued capital expenditures		295		-
Accrued pharma services invoices		293		108
Taxes payable		289		334
Accrued lab costs - diagnostics		172		161
Financing lease liability		117		177
ESPP payable		88		108
Accrued sales and marketing - diagnostics		78		51
Deferred revenue		43		54
Total other accrued expenses	$	9,407	$	9,795

Long-term liabilities consisted of the following as of June 30, 2021 and December 31, 2020:

SCHEDULE OF LONG TERM LIABILITIES

	June 30, 2021		December 31, 2020
		(unaudited)
Uncertain tax positions	$	4,454	$	4,342
Warrant liability		230		21
Other		92		138
Deferred revenue		25		136
Total other long-term liabilities	$	4,801	$	4,637